Study #2020-1136
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, Fludarabine, KITE-363
Description
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-363, in participants with relapsed and/or refractory B-cell lymphoma.
Information and next steps
Disease:
Relapsed and/or Refractory B-cell Lymphoma
Study phase:
I
Physician name:
Loretta Nastoupil
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.